Mayo score

May 18, 2020May 18, 2020

Early Phase 2 Trial Data Support Safety, Efficacy of BBT-401 for Ulcerative Colitis

News, Ulcerative colitis

People with ulcerative colitis may benefit from the experimental oral therapy BBT-401, suggest early data from an ongoing Phase 2 clinical trial that also supports its good safety profile. BBT-401 is ... Read more

October 2, 2019October 2, 2019

Entyvio Seen as Superior to Humira in Treating Active UC, Phase 3 Trial Shows

News

One year of treatment with Entyvio (vedolizumab) was found to be superior to Humira (adalimumab) in achieving disease remission in people with ulcerative colitis (UC), a common form of inflammatory bowel disease (IBD), Takeda ... Read more

August 30, 2019August 30, 2019

InDex’s Cobitolimod Meets Primary Endpoint of Clinical Remission in Ulcerative Colitis Study, Results Show

News

A larger proportion of people treated with the highest dose of InDex Pharmaceuticals‘ investigational therapy cobitolimod achieved clinical remission compared with those treated with placebo, according to the results of ... Read more

March 16, 2018March 16, 2018

Protalix Alleviates Ulcerative Colitis, Sending Some Cases Into Remission, Phase 2 Trial Shows

News

Protalix BioTherapeutics’ OPRX-106 alleviated ulcerative colitis and in some cases sent it into remission, a Phase 2 clinical trial shows . OPRX-106 is a TNF inhibitor that Protalix scientists grew from ... Read more

October 3, 2017

Seres’ SER-287 for UC Shows Positive Results in Phase 1b Trial

News

Seres Therapeutics announced positive topline results from the company’s Phase 1b placebo-controlled study investigating the effects of SER-287, a potential microbiome therapy, in patients with ulcerative colitis (UC) who failed ... Read more